19. Lack of Transparency
Throughout the opioid crisis, pharmaceutical companies maintained a shroud of secrecy around their operations. They often withheld or obscured critical information about sales volumes, marketing practices, and adverse events from both regulators and the public. As revealed by The Guardian, this lack of transparency hindered efforts to detect misuse patterns early and delayed interventions that could have saved lives.
